Created with Highcharts 11.1.0Apr '24Jul '24Oct '24Jan '25100.0067.80

Profile

Edit
BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.
URL https://www.biomarin.com
Investor Relations URL https://investors.biomarin.com/
HQ State/Province California
Sector Health Care
Industry Biotechnology
Next Earnings Release Apr. 24, 2025 (est.)
Last Earnings Release Feb. 19, 2025
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Edit
BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.
URL https://www.biomarin.com
Investor Relations URL https://investors.biomarin.com/
HQ State/Province California
Sector Health Care
Industry Biotechnology
Next Earnings Release Apr. 24, 2025 (est.)
Last Earnings Release Feb. 19, 2025
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A
Quickflows